The Texas Medication Algorithm Project (TMAP)
From dKosopedia
The Texas Medication Algorithm Project (TMAP) is a pilot program where a recommended medication practice was developed in Texas and already exported to several other states.
The TMAP medication guidelines were established in 1995 as an "expert consensus" based on the opinions of prescribers, rather than an analysis of scientific studies.
The pharmaceutical companies who funded the scheme include Janssen Pharmaceutica, Johnson & Johnson, Eli Lilly, Astrazeneca, Pfizer, Novartis, Janssen-Ortho-McNeil, GlaxoSmithKline, Abbott, Bristol Myers Squibb, Wyeth-Ayerst and Forrest Laboratories.
The drugs recommended as "first line treatment", many of them with potentially deadly side effects, are patented expensive drugs produced by the sponsors of the guidelines: Risperdal, Zyprexa, Seroqual, Geodone, Depakote, Paxil, Zoloft, Celexa, Wellbutron, Zyban, Remeron, Serzone, Effexor, Buspar, Adderall and Prozac.
The Texas project, which promotes the use of newer, more expensive antidepressants and antipsychotic drugs, sparked off controversy when Allen Jones, an employee of the Pennsylvania Office of the Inspector General, revealed that key officials with influence over the medication plan in his state received money and perks from drug companies with a stake in the medication algorithm
LInks
Drug company targets US state health officials